Asthma Clinical Trial
Official title:
Kansas City Community Environmental Remediation And Training (KC CERT)
Verified date | January 2021 |
Source | Children's Mercy Hospital Kansas City |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Objective: Our overall objective is to test the hypothesis that the health of children with chronic respiratory symptoms or chronic exposures to environmental hazards can be improved through a combination of standard home maintenance interventions and a set of interim controls and targeted repair interventions. I. Background: The Bi-State Kansas City Enhanced Enterprise Community (KCEEC) is one of pervasive poverty, unemployment and general distress. This same area is also an area of poor environmental health with a disproportionate number of children with lead poisoning, asthma, and home injuries. In May 2001, the Metropolitan (Kansas City) Health Council released a report urging the implementation of strategies to address this growing concern. They stated, "Environmental assessments and interventions in homes, schools, and workplaces are needed to promote indoor air quality and thereby help prevent asthma and asthma flare-ups," in combination with the need for, "trained community-based peer educators needed to work with families/communities in areas of high asthma incidence,". The need for major rehabilitation is echoed in the 1999 Consolidated Plan, as well as by most community development and housing officials. The KC CERT project responds to these concerns by demonstrating low-cost, replicable intervention strategies that can have an impact on the health and safety of children and their families. By providing training and employment opportunities to residents in high-risk areas to assess, prevent and remediate environmental hazards, this project promotes sustained systematic change within the KCEEC.
Status | Terminated |
Enrollment | 200 |
Est. completion date | May 2005 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 17 Years |
Eligibility | Inclusion Criteria: Participants that qualify for the study will have one of the following health conditions: - Persistent asthma as defined by NHLBI guidelines - Chronic respiratory symptoms, - And/or have lead levels equal to or above 15 micrograms per deciliter. - They must be between the ages of 2 and 17 years of age - Stay in the home a minimum of 4 nights per week - They should reside in the KCEEC (Defined as the city limits of Kansas City Kansas or Kansas City Missouri). - They will also have lived in the same housing, either rental or self-owned, for at least 6 months and have a reasonable expectation of remaining in this housing for at least one additional year. To qualify for the intervention phase of the study done by HHN, - The home must have no more than $2000 estimated intervention costs. Examples of houses that would not qualify include: A house that needs a new roof, a house with extensive amounts of flaking lead paint, a house with significant structural problems. Exclusion Criteria: - Any children who do not meet the age and residency requirements. - Any home with more than $2000 worth of maintenance and repair problems. - Any home with emergent, life threatening conditions. - Children with other chronic diseases (leukemia, diabetes etc) will be referred through the HHN and CMH to appropriate medical services, agencies, organizations and other community resources. |
Country | Name | City | State |
---|---|---|---|
United States | Children's Mercy Hospital | Kansas City | Missouri |
Lead Sponsor | Collaborator |
---|---|
Children's Mercy Hospital Kansas City | The healthy Homes Network of Kansas City, Missouri, US Department of Housing and Urban Development |
United States,
Portnoy JM, Kwak K, Dowling P, VanOsdol T, Barnes C. Health effects of indoor fungi. Ann Allergy Asthma Immunol. 2005 Mar;94(3):313-9; quiz 319-22, 390. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction in home airborne fungal spore levels. | |||
Primary | Reduction in home allergen exposure. | |||
Secondary | Reduction in healthy care utilization | |||
Secondary | Improvement in quality of life |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|